172 related articles for article (PubMed ID: 12592351)
1. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
Zwaan CM; Reinhardt D; Jürgens H; Huismans DR; Hählen K; Smith OP; Biondi A; van Wering ER; Feingold J; Kaspers GJ
Leukemia; 2003 Feb; 17(2):468-70. PubMed ID: 12592351
[No Abstract] [Full Text] [Related]
2. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia.
Cotter M; Rooney S; O'Marcaigh A; Smith OP
Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727
[No Abstract] [Full Text] [Related]
3. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M
Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
6. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
8. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Larson RA; Boogaerts M; Estey E; Karanes C; Stadtmauer EA; Sievers EL; Mineur P; Bennett JM; Berger MS; Eten CB; Munteanu M; Loken MR; Van Dongen JJ; Bernstein ID; Appelbaum FR;
Leukemia; 2002 Sep; 16(9):1627-36. PubMed ID: 12200674
[TBL] [Abstract][Full Text] [Related]
9. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier P; Robillard N; Ayari S; Guillaume T; Delaunay J; Mechinaud F; Avet-Loiseau H; Mohty M; Harousseau JL; Garand R
Br J Haematol; 2008 Dec; 143(5):744-6. PubMed ID: 19036018
[No Abstract] [Full Text] [Related]
10. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
11. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
Cheung KC; Wong LG; Yeung YM
Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
16. New developments in antibody therapy for acute myeloid leukemia.
Tomblyn MR; Tallman MS
Semin Oncol; 2003 Aug; 30(4):502-8. PubMed ID: 12939719
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
18. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
[TBL] [Abstract][Full Text] [Related]
19. New developments in the treatment of acute myeloid leukemia.
Radich J; Sievers E
Oncology (Williston Park); 2000 Nov; 14(11A):125-31. PubMed ID: 11195406
[TBL] [Abstract][Full Text] [Related]
20. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
